Literature DB >> 29074209

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor.

Alessandra Bearz1, Elisa De Carlo2, Roberto Doliana3, Monica Schiappacassi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29074209     DOI： 10.1016/j.jtho.2017.07.017

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.

Authors:  Emna Mahfoudhi; Charles Ricordel; Gwendoline Lecuyer; Cécile Mouric; Hervé Lena; Rémy Pedeux
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

2.  Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report.

Authors:  Elisa De Carlo; Monica Schiappacassi; Martina Urbani; Roberto Doliana; Gustavo Baldassarre; Valentina Da Ros; Sandra Santarossa; Emanuela Chimienti; Eleonora Berto; Lucia Fratino; Alessandra Bearz
Journal:  Onco Targets Ther       Date:  2018-12-10       Impact factor: 4.147

3.  Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma.

Authors:  Xisheng Fang; Xia Liu; Chengyin Weng; Yong Wu; Baoxiu Li; Haibo Mao; Mingmei Guan; Lin Lu; Guolong Liu
Journal:  Int J Med Sci       Date:  2020-09-23       Impact factor: 3.738

4.  Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.

Authors:  Naoyuki Nishiya; Yusuke Oku; Chie Ishikawa; Tsutomu Fukuda; Shingo Dan; Tetsuo Mashima; Masaru Ushijima; Yoko Furukawa; Yuka Sasaki; Keishi Otsu; Tomoko Sakyo; Masanori Abe; Honami Yonezawa; Fumito Ishibashi; Masaaki Matsuura; Akihiro Tomida; Hiroyuki Seimiya; Takao Yamori; Masatomo Iwao; Yoshimasa Uehara
Journal:  Cancer Sci       Date:  2021-03-24       Impact factor: 6.716

5.  Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions.

Authors:  Mengyao Sun; Xu Wang; Yinghui Xu; Chao Sun; Ye Guo; Shi Qiu; Renshan Zhao; Wenhao Zhu; Kewei Ma
Journal:  Thorac Cancer       Date:  2021-12-27       Impact factor: 3.500

6.  Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

Authors:  Silvia La Monica; Roberta Minari; Daniele Cretella; Mara Bonelli; Claudia Fumarola; Andrea Cavazzoni; Maricla Galetti; Graziana Digiacomo; Federica Riccardi; Pier Giorgio Petronini; Marcello Tiseo; Roberta Alfieri
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

7.  MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.

Authors:  Akihiro Nishiyama; Shinji Takeuchi; Yuta Adachi; Sakiko Otani; Azusa Tanimoto; Motoko Sasaki; Shingo Matsumoto; Koichi Goto; Seiji Yano
Journal:  Cancer Sci       Date:  2020-09-01       Impact factor: 6.716
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.